- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Septerna, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Mi | Septerna, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Septerna, Inc.: Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 61 | GlobeNewswire (Europe) | Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule... ► Artikel lesen | |
| Di | Septerna started by J.P. Morgan at overweight, GPCR platform cited | 3 | Seeking Alpha | ||
| Di | Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones | 1 | Benzinga.com | ||
| 31.10. | Nasdaq debutante Septerna swells its IPO to $331m | 4 | pharmaphorum | ||
| 30.10. | Septerna, Inc.: Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering | 49 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral... ► Artikel lesen | |
| 30.10. | IPO Radar: Septerna, Swiggy and Horizon Robotics | 7 | The Armchair Trader | ||
| SEPTERNA Aktie jetzt für 0€ handeln | |||||
| 28.10. | Septerna verzeichnet Aktienkäufe im Wert von 11,7 Millionen US-Dollar durch Third Rock Ventures | 4 | Investing.com Deutsch | ||
| 28.10. | Septerna, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10. | IPO Roundup: Brazil Potash, Septerna and more | 3 | Seeking Alpha | ||
| 25.10. | Septerna, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.10. | Septerna's Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs | 2 | MedCity News | ||
| 25.10. | Septerna Shares Jump 42% After IPO Shows Biotech Still Hot | 2 | BNN Bloomberg | ||
| 25.10. | Septerna's $288M IPO is another sign of the market warming to biotech investment | 4 | FierceBiotech | ||
| 25.10. | GPCR-focused biotech Septerna prices further upsized IPO at $18 | 3 | Renaissance Capital | ||
| 25.10. | GPCR drugmaker Septerna amasses $288M in IPO | 7 | BioPharma Dive | ||
| 25.10. | Septerna Prices IPO Of 16.00 Mln Shares At $18.00/shr | 3 | RTTNews | ||
| 25.10. | Septerna, Inc.: Septerna Prices Upsized Initial Public Offering | 307 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral... ► Artikel lesen | |
| 24.10. | GPCR-focused biotech Septerna ups proposed deal size by 57% ahead of $275 million IPO | 3 | Renaissance Capital |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,870 | -0,35 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
| QIAGEN | 39,995 | +2,97 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
Das Unternehmen SEPTERNA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 22,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SEPTERNA INC finden Sie auf Wallstreet Online.
